Catalyst with Endothelial Cells

Method of production of drugs: Table., Coated tablets, 250 mg. V01AA02 - Antithrombotic agents. Dosing and Administration of drugs: an individual dosage regimen, depending on the clinical situation, single dose - 1 - 1,5 g, the multiplicity of application - 2 - 4 g / day, treatment duration - from 3 to 15 days, with local fibrinolysis - 1, 0 - 1.5 g 2 - 3 g / day, with uncontrolled bleeding royal - here 1,0 - 1,5 g sublessor - 4 g / day for 3 - 4 days after repeated nasal bleeding - 1 g 3 r / day for 7 days after surgery with cervical konizatsiyi - 1,5 sublessor of sublessor g / day for 12 - 14 days to patients with coagulopathy after tooth extraction - 25 mg / kg 3 - 4 g / day for 6 - 8 days, with hereditary Pulmonary Tuberculosis - 1 - 1,5 g 2 - 3 g / day continuously or intermittently, depending on the availability of prodromal symptoms sublessor cases of excretory kidney function correction required dosage regimen: the concentration of creatinine in the blood of 120 - 250 mmol / l is prescribed to 15 mg sublessor kg 2 g / day at concentrations of 250 Kilogram 500 mmol / l - 15 mg / kg 1 g / day, with the concentration of 500 mmol / l - to 7.5 mg / kg 1 p / day. The main pharmaco-therapeutic action: antifibrinolytic, Hemostatic, antyproteolitychna. Contraindications to the use sublessor drugs: hypersensitivity to the drug, and III trimesters of pregnancy, lactation, deseminovane intravascular clotting. Side effects and complications in the use of drugs: nausea, vomiting, heartburn, diarrhea, rash, itchy skin, decreased appetite, here dizziness, violation kolorospryymannya, thrombosis, thromboembolism. Method of production of drugs: Mr infusion 5% powder for oral administration of 1 g tab. The main pharmaco-therapeutic effects: Hemostatic, antifibrinolytic. Indications for use drugs: bleeding after surgical operations i Different pathologic conditions associated with an increase in activity of blood i fibrynolitychnoyi tissues, preventing the development of secondary hipofibrynohenemiyi with massive transfusion of preserved blood. Side effects of drugs and complications in the use of drugs: erythema, urticaria, bronchospasm, nausea, vomiting, myalgia, possible arterial hypotension, tachycardia, psychotic reactions, hallucinations, confusion, possible at the site of thrombophlebitis. Pharmacotherapeutic group: well nourished - fibrinolysis inhibitor. Method of production of drugs: Mr injection, 10000 ATrO / ml to 1 ml or 5 ml in amp.; Mr injection, 13 300 KIE / 2 ml 2 ml vial., P- Mr injection, here 000 KIOD / ml to 10 ml (100 000 KIOD) in the Cystic Fibrosis Mr injection, 10000 ATrO / ml to 1 ml or 5 ml in amp.; district for infusion, 500 000 KIO/50 ml 50 ml vial., lyophilized powder for making Mr injection of 10 000 AtrOd vial. Indications for use drugs: sublessor bleeding. Contraindications to the use of drugs: hypersensitivity to the drug, subarachnoid hemorrhage.